series-a
Stage
1
Investors
About
Develops first-in-class non-coding RNA medicines targeting obesity and metabolic diseases.
Explore Resalis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.